Comparative Pharmacology
Head-to-head clinical analysis: DANYELZA versus EMPLICITI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANYELZA versus EMPLICITI.
DANYELZA vs EMPLICITI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disialoganglioside GD2-binding monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-positive tumor cells.
Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.
1.5 mCi/kg (0.037 MBq/kg) intravenously over 30 minutes on days 1, 3, and 5 of each 28-day cycle.
10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.
None Documented
None Documented
Terminal elimination half-life is approximately 29 days (range 25–35 days) at steady state, supporting a weekly dosing schedule for maintaining therapeutic concentrations.
Terminal elimination half-life is approximately 26-29 days. This long half-life supports biweekly IV dosing after initial weekly schedule.
Renal elimination accounts for approximately 80% of the administered dose as unchanged drug; the remaining 20% is excreted via the biliary/fecal route.
Empliciti (elotuzumab) is a monoclonal antibody; elimination occurs via intracellular catabolism, yielding amino acids. Renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion is minimal; no specific data on percentage.
Category C
Category C
Monoclonal Antibody Antineoplastic
Monoclonal Antibody Antineoplastic